Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740401 | 0.76 | TDP1 (0.37) | FFAR3LCKFYNTDP1HSD17B10 | |
| SCHEMBL8642402 | 0.75 | TDP1 (0.38) | FFAR3LCKFYNTDP1ALDH1A1 | |
| Acetic Acid SCHEMBL31372161 | 0.74 | FFAR3 (0.58) | FFAR3LCKFYNLMNA | |
| SCHEMBL1705614 | 0.73 | ALDH1A1 (0.33) | TDP1HSD17B10ALDH1A1 | |
| SCHEMBL8426644 | 0.72 | FFAR3 (0.43) | FFAR3LCKFYNLMNA | |
| SCHEMBL1771329 | 0.71 | — | — | |
| SCHEMBL316537 | 0.69 | CA1 (0.40) | FFAR3LCKFYN | |
| Bicarbonate SCHEMBL11155878 | 0.65 | FFAR3 (0.55) | FFAR3LCKFYNTDP1HSD17B10 | |
| Bicarbonate SCHEMBL319706 | 0.65 | — | — | |
| Acetic Acid SCHEMBL21175529 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | FFAR3 378/4885LCK 794/4885FYN 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.